Literature DB >> 1381312

Mouse tumor rejection antigens P815A and P815B: two epitopes carried by a single peptide.

B Lethé1, B van den Eynde, A van Pel, G Corradin, T Boon.   

Abstract

Mouse mastocytoma P815 expresses several distinct tumor rejection antigens recognized by syngeneic cytolytic T lymphocytes (CTL). Two of these tumor rejection antigens, P815A and P815B, are encoded by gene P1A, the sequence of which was reported previously. Tumor cell variants having lost one or both of these antigens were isolated by in vitro selection with CTL and also by collecting tumor cells that progressed in vivo after escaping a nearly complete immune rejection process. The structure of gene P1A in these antigen-loss variants was examined. Several A-B- variants presented a complete or partial deletion of the gene. One variant that had lost only antigen A displayed a point mutation in the first exon. Peptides were synthesized that corresponded to the normal sequence located in the region of this point mutation. They sensitized target cells to both anti-A and anti-B CTL. The homologous peptide encoded by the mutated gene of the P815 A-B+ variant sensitized cells only to anti-B CTL. We conclude that anti-A and anti-B CTL recognize on the same peptide two distinct epitopes that are affected differently by the mutation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1381312     DOI: 10.1002/eji.1830220916

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  28 in total

1.  Dose-dependent and schedule-dependent effects of interleukin-12 on antigen-specific CD8 responses.

Authors:  K Lee; W W Overwijk; M O'Toole; H Swiniarski; N P Restifo; A J Dorner; S F Wolf; K Sturmhoefel
Journal:  J Interferon Cytokine Res       Date:  2000-06       Impact factor: 2.607

2.  Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes.

Authors:  Xue-Feng Bai; Jinqing Liu; Ou Li; Pan Zheng; Yang Liu
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

3.  B7-CTLA4 interaction enhances both production of antitumor cytotoxic T lymphocytes and resistance to tumor challenge.

Authors:  P Zheng; Y Wu; Y Guo; C Lee; Y Liu
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

4.  Mutated mitogen-activated protein kinase: a tumor rejection antigen of mouse sarcoma.

Authors:  H Ikeda; N Ohta; K Furukawa; H Miyazaki; L Wang; K Kuribayashi; L J Old; H Shiku
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

5.  The development and functions of CD4(+) T cells expressing a transgenic TCR specific for an MHC-I-restricted tumor antigenic epitope.

Authors:  Xue Han; Peiying Ye; Liqun Luo; Linghua Zheng; Yang Liu; Lieping Chen; Shengdian Wang
Journal:  Cell Mol Immunol       Date:  2011-05-30       Impact factor: 11.530

Review 6.  MHC ligands and peptide motifs: first listing.

Authors:  H G Rammensee; T Friede; S Stevanoviíc
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

Review 7.  Enhancing the recognition of tumour associated antigens.

Authors:  N P Restifo; B R Minev; A S Taggarse; B J McFarland; M Wang; K R Irvine
Journal:  Folia Biol (Praha)       Date:  1994       Impact factor: 0.906

8.  Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40.

Authors:  Yan Yang; Chengwen Liu; Weiyi Peng; Gregory Lizée; Willem W Overwijk; Yang Liu; Scott E Woodman; Patrick Hwu
Journal:  Blood       Date:  2012-08-30       Impact factor: 22.113

9.  Photodynamic therapy of murine mastocytoma induces specific immune responses against the cancer/testis antigen P1A.

Authors:  Pawel Mroz; Fatma Vatansever; Angelika Muchowicz; Michael R Hamblin
Journal:  Cancer Res       Date:  2013-09-26       Impact factor: 12.701

10.  Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL.

Authors:  K R Irvine; B J McCabe; S A Rosenberg; N P Restifo
Journal:  J Immunol       Date:  1995-05-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.